交银国际每日晨报-20250429

Group 1: 康方生物 (Kangfang Biologics) - The approval for the listing application of Ivosidenib for 1L PD-L1 positive NSCLC in mainland China was granted earlier than expected, with the first interim overall survival (OS) data showing a hazard ratio (HR) of 0.777, indicating a 22.3% reduction in the risk of death [1][2] - The market should focus on the subsequent and final OS analysis results, as the current interim analysis has a low alpha value and a small sample size [1] - The successful approval reflects the regulatory body's recognition of the trend in OS benefits, suggesting limited impact on the clinical and commercial value of Ivosidenib in the mainland market from future OS HR results [1] Group 2: 卓胜微 (Zhuosheng Micro) - In Q1 2025, the revenue decreased by 36.5% year-on-year to 756 million RMB, primarily due to weaker seasonal changes in 2024 [3] - The company reported a net loss of 47 million RMB, transitioning from profit to loss, with a non-recurring net profit loss of 54 million RMB and a gross margin of 31.0%, down 540 basis points quarter-on-quarter [3] - Management anticipates a significant revenue increase in the second half of 2025, driven by seasonal demand for RF products and the launch of new products like PAMiD [3][4] Group 3: 中国太保 (China Pacific Insurance) - In Q1, the net profit attributable to shareholders decreased by 18.1% year-on-year, mainly due to a 15% decline in investment income [8] - The new business value grew by 11.3% year-on-year, with a comparable growth of 39.0%, indicating strong performance in the insurance sector [8] - The comprehensive cost ratio for property and casualty insurance improved, with a combined ratio of 97.4%, down 0.6 percentage points year-on-year [8] Group 4: 中国平安保险 (Ping An Insurance) - The operating profit attributable to shareholders grew by 2.4% year-on-year, primarily driven by the life and health insurance sectors [9] - The net profit attributable to shareholders decreased by 26.4% year-on-year, significantly lower than the operating profit growth [9] - The new business value growth exceeded expectations, with a significant improvement in the value rate, and the comprehensive cost ratio for property and casualty insurance showed notable improvement [9] Group 5: 新奧能源 (Xinao Energy) - In Q1, the retail gas volume increased by 0.3% year-on-year, outperforming the 2.2% decline in apparent natural gas consumption in mainland China [10] - The company experienced a 16% year-on-year decrease in new residential connections, which was within expectations [10] - The privatization plan is progressing steadily, with expectations for shareholder approval in Q4 of this year [10]